Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis



Status:Completed
Conditions:Colitis, Colitis, Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - 80
Updated:8/29/2018
Start Date:January 8, 2016
End Date:August 21, 2018

Use our guide to learn which trials are right for you!

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, With a Vedolizumab IV Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy

The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab
SC) maintenance treatment in participants with moderately to severely active ulcerative
colitis (UC) who achieved clinical response following administration of vedolizumab
intravenous (vedolizumab IV) induction therapy.

The drug being tested in this study is called vedolizumab subcutaneous (vedolizumab SC).
Vedolizumab SC is being tested to treat people who have moderate to severely active
ulcerative colitis. This study will look at clinical remission as well as mucosal healing,
durable clinical response, durable clinical remission, and corticosteroid free remission in
participants with UC who receive vedolizumab SC maintenance therapy after having achieved a
clinical response to vedolizumab IV induction therapy.

The study will enroll approximately 400 patients. All participants will enter into a 6 week
Induction Phase where they will be administered open-label vedolizumab IV 300 mg via
intravenous infusion (IV) at Week 0 (Day 1) and Week 2 (day 15), and will then be assessed
for a clinical response at Week 6. Participants who achieve a clinical response at Week 6
will be randomly assigned to one of the three treatment groups:

- Vedolizumab SC 108 mg Q2W and Placebo IV Q8W

- Vedolizumab IV 300 mg Q8W and Placebo SC Q2W

- Placebo SC Q2W and Placebo IV Q8W

Participants who do not achieve a clinical response at Week 6 will not be randomized in to
the Maintenance Period, and will receive a third infusion of vedolizumab IV 300 mg at Week 6.

This multi-center trial will be conducted worldwide. The overall time to participate in this
study is up to 71 weeks. Participants will make multiple visits to the clinic, plus a final
visit 18 weeks after last dose of study drug for a follow-up assessment. Participants will
also participate in a long-term safety follow-up, by phone, at 6 months after the last dose
of study drug.

Inclusion Criteria:

1. Diagnosis of ulcerative colitis (UC) established at least 6 months prior to screening,
by clinical and endoscopic evidence and corroborated by a histopathology report.

2. Moderately to severely active UC as determined by a complete Mayo score of 6-12 (with
an endoscopic subscore ≥2)

3. Evidence of UC extending proximal to the rectum (≥15 cm of involved colon).

4. Inadequate response with, loss of response to, or intolerance to corticosteroids,
immunomodulators, or Tumor Necrosis Factor-alpha (TNF-α) antagonists

Exclusion Criteria:

1. Evidence of abdominal abscess or toxic megacolon at the initial Screening Visit.

2. Extensive colonic resection, subtotal or total colectomy.

3. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.

4. Prior exposure to investigational or approved non-biologic therapies (eg,
cyclosporine, tacrolimus, thalidomide, methotrexate or tofacitinib) for the treatment
of underlying disease within 30 days or 5 half-lives of screening (whichever is
longer).

5. Prior exposure to any investigational or approved biologic or biosimilar agent within
60 days or 5 half-lives of screening (whichever is longer).

6. Prior exposure to vedolizumab

7. Surgical intervention for UC required at any time during the study.

8. History or evidence of adenomatous colonic polyps that have not been removed, or has a
history or evidence of colonic mucosal dysplasia.

9. Suspected or confirmed diagnosis of Crohn's entercolitis, indeterminate colitis,
ischaemic colitis, radiation colitis, diverticular disease associated with colitis, or
microscopic colitis.

10. Active infections

11. Chronic hepatitis B virus (HBV) infection or chronic hepatitis C virus (HCV)
infection, HIV or tuberculosis (active or latent), identified congenital or acquired
immunodeficiency. HBV immune participants (ie, being hepatitis B surface antigen
[HBsAg] negative and hepatitis B antibody positive) may, however, be included.

12. History of any major neurological disorders, including stroke, multiple sclerosis,
brain tumor, demyelinating or neurodegenerative disease.
We found this trial at
29
sites
?
mi
from
Seattle, WA
Click here to add this to my saved trials
112 Gainsborough Square
Chesapeake, Virginia 23320
757-547-0798
?
mi
from
Chesapeake, VA
Click here to add this to my saved trials
610 3rd St # 206
Macon, Georgia 31201
?
mi
from
Macon, GA
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
701 West Morse Boulevard
Winter Park, Florida 32789
?
mi
from
Winter Park, FL
Click here to add this to my saved trials
Atlanta, Georgia 30342
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Belton, Missouri 64012
?
mi
from
Belton, MO
Click here to add this to my saved trials
Chesterfield, Michigan 48098
?
mi
from
Chesterfield, MI
Click here to add this to my saved trials
?
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Ciudad Autonoma Buenos Aires, C1128
?
mi
from
Ciudad Autonoma Buenos Aires,
Click here to add this to my saved trials
Crestview Hills, Kentucky 41017
?
mi
from
Crestview Hills, KY
Click here to add this to my saved trials
Dayton, Ohio 45415
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Germantown, Tennessee 38138
?
mi
from
Germantown, TN
Click here to add this to my saved trials
Great Neck, New York 11021
?
mi
from
Great Neck, NY
Click here to add this to my saved trials
Inverness, Florida 34452
?
mi
from
Inverness, FL
Click here to add this to my saved trials
?
mi
from
Largo, FL
Click here to add this to my saved trials
Little Rock, Arkansas 72204
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Miami, Florida 33144
?
mi
from
Miami, FL
Click here to add this to my saved trials
410 Saybrook Road
Middletown, Connecticut 06457
?
mi
from
Middletown, CT
Click here to add this to my saved trials
Naples, Florida 34102
?
mi
from
Naples, FL
Click here to add this to my saved trials
1200 Breckenridge Street
Owensboro, Kentucky 42303
?
mi
from
Owensboro, KY
Click here to add this to my saved trials
243 N Rd
Poughkeepsie, New York 12601
(845) 471-9410
Premier Medical Group of the Hudson Valley Premier Medical Group offers comprehensive, integrated care providing...
?
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
?
mi
from
Suwanee, GA
Click here to add this to my saved trials
?
mi
from
Topeka, KS
Click here to add this to my saved trials
Tulsa, Oklahoma 74137
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
?
mi
from
Tyler, TX
Click here to add this to my saved trials
Wheat Ridge, Colorado 80033
?
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
?
mi
from
Wyoming, MI
Click here to add this to my saved trials